Literature DB >> 15350002

Long-term results and modeling to predict outcomes in recipients with HCV infection: results of the NIDDK liver transplantation database.

Michael Charlton1, Kris Ruppert, Steven H Belle, Nathan Bass, Daniel Schafer, Russell H Wiesner, Katherine Detre, Yuling Wei, James Everhart.   

Abstract

Hepatitis C virus (HCV)-associated liver disease is the most common indication for liver transplantation (LT). There are, however, no long-term (>5 year) studies of comparative outcomes for recipients with HCV infection, and no models capable of identifying recipients with HCV infection at greatest risk for adverse outcomes. We prospectively determined: 1) long-term outcomes, and 2) whether pretransplant patient or donor variables can be used to predict death and/or graft loss in recipients with HCV infection. A total of 165 HCV-infected recipients were eligible for this study. Pretransplant donor and recipient characteristics and patient and graft survival data were prospectively collected. Model building for outcomes was carried out using logistic regression. Receiver operating characteristic curves for different models were created and compared. Median follow-up was 8.5 years. Adjusted 10 year graft survival was 64% for recipients with HCV infection and 51% for uninfected recipients. A model incorporating pretransplant HCV ribonucleic acid (RNA), cytomegalovirus immunoglobulin (CMV IgG) serostatus, creatinine, bilirubin, prothrombin time international ratio (INR), recipient age, and donor age was developed to identify recipients at greatest risk of short-term mortality or graft loss (area under receiver operating characteristic curve = .83) In conclusion, long-term outcomes following LT for recipients with HCV infection are comparable to those for recipients undergoing LT for other indications. HCV-infected recipients at greatest risk for short-term mortality and graft loss can be identified using several readily identifiable pretransplant variables. Long-term death and graft loss specifically secondary to recurrence of HCV appears, however, to be determined primarily by factors other than those included in this analysis.

Entities:  

Mesh:

Year:  2004        PMID: 15350002     DOI: 10.1002/lt.20211

Source DB:  PubMed          Journal:  Liver Transpl        ISSN: 1527-6465            Impact factor:   5.799


  17 in total

1.  Evolution of causes and risk factors for mortality post-liver transplant: results of the NIDDK long-term follow-up study.

Authors:  K D S Watt; R A Pedersen; W K Kremers; J K Heimbach; M R Charlton
Journal:  Am J Transplant       Date:  2010-05-10       Impact factor: 8.086

Review 2.  Recurrent hepatitis C after liver transplant.

Authors:  Andrew S deLemos; Paul A Schmeltzer; Mark W Russo
Journal:  World J Gastroenterol       Date:  2014-08-21       Impact factor: 5.742

Review 3.  Recurrent hepatitis C post-transplantation: where are we now and where do we go from here? A report from the Canadian transplant hepatology workshop.

Authors:  Kymberly D S Watt; Kelly Burak; Marc Deschênes; Les Lilly; Denis Marleau; Paul Marotta; Andrew Mason; Kevork M Peltekian; Eberhard L Renner; Eric M Yoshida
Journal:  Can J Gastroenterol       Date:  2006-11       Impact factor: 3.522

4.  Affinity maturation to improve human monoclonal antibody neutralization potency and breadth against hepatitis C virus.

Authors:  Yong Wang; Zhen-Yong Keck; Anasuya Saha; Jinming Xia; Fraser Conrad; Jianlong Lou; Michael Eckart; James D Marks; Steven K H Foung
Journal:  J Biol Chem       Date:  2011-10-14       Impact factor: 5.157

5.  Advancing the high throughput identification of liver fibrosis protein signatures using multiplexed ion mobility spectrometry.

Authors:  Erin Shammel Baker; Kristin E Burnum-Johnson; Jon M Jacobs; Deborah L Diamond; Roslyn N Brown; Yehia M Ibrahim; Daniel J Orton; Paul D Piehowski; David E Purdy; Ronald J Moore; William F Danielson; Matthew E Monroe; Kevin L Crowell; Gordon W Slysz; Marina A Gritsenko; John D Sandoval; Brian L Lamarche; Melissa M Matzke; Bobbie-Jo M Webb-Robertson; Brenna C Simons; Brian J McMahon; Renuka Bhattacharya; James D Perkins; Robert L Carithers; Susan Strom; Steven G Self; Michael G Katze; Gordon A Anderson; Richard D Smith
Journal:  Mol Cell Proteomics       Date:  2014-01-08       Impact factor: 5.911

6.  Infections in liver transplant recipients.

Authors:  Fabian A Romero; Raymund R Razonable
Journal:  World J Hepatol       Date:  2011-04-27

7.  Post-transplant survival is improved for hepatitis C recipients who are RNA negative at time of liver transplantation.

Authors:  Brett E Fortune; Alvaro Martinez-Camacho; Sarah Kreidler; Jane Gralla; Gregory T Everson
Journal:  Transpl Int       Date:  2015-04-16       Impact factor: 3.782

8.  High sustained virological response to pegylated interferon and ribavirin for recurrent genotype 3 hepatitis C infection post-liver transplantation.

Authors:  Nabiha Faisal; Khalid Mumtaz; Max Marquez; Eberhard L Renner; Leslie B Lilly
Journal:  Hepatol Int       Date:  2014-11-29       Impact factor: 6.047

9.  A SPECIAL MEETING REVIEW EDITION: Advances in the Treatment of Hepatitis C Virus Infection From EASL 2014: The 49th Annual Meeting of the European Association for the Study of the Liver • April 9-13, 2014 • London, United KingdomSpecial Reporting on:• SAPPHIRE II: Phase 3 Placebo-Controlled Study of Interferon-Free, 12-Week Regimen of ABT-450/R/ABT-267, ABT-333, and Ribavirin in Treatment-Experienced Adults With Hepatitis C Virus Genotype 1• All Oral Fixed-Dose Combination Sofosbuvir/Ledipasvir With or Without Ribavirin for 12 or 24 Weeks in Treatment-Naive Genotype 1 HCV-Infected Patients: the Phase 3 ION-1 Study• PEARL-III: 12 Weeks of ABT-450/R/267 + ABT-333 Achieved SVR in >99% of 419 Treatment-Naive HCV Genotype 1B-Infected Adults With or Without Ribavirin• Results of the Phase 2 Study M12-999: Interferon-Free Regimen of ABT-450/R/ABT-267 + ABT-333 + Ribavirin in Liver Transplant Recipients With Recurrent HCV Genotype 1 Infection• Sofosbuvir and Ribavirin for the Treatment of Chronic HCV With Cirrhosis and Portal Hypertension With and Without Decompensation: Early Virologic Response and Safety• All-Oral Dual Therapy With Daclatasvir and Asunaprevir in Patients With HCV Genotype 1B Infection: Phase 3 Study Results• Sofosbuvir/Ledipasvir Fixed Dose Combination Is Safe and Effective in Difficult-to-Treat Populations Including Genotype-3 Patients, Decompensated Genotype-1 Patients, and Genotype-1 Patients With Prior Sofosbuvir Treatment Experience• Sofosbuvir and Ribavirin for the Treatment of Recurrent Hepatitis C Infection After Liver Transplantation: Results of a Prospective, Multicenter StudyPLUS Meeting Abstract Summaries With Expert Commentary by: Steven L. Flamm, MDChief, Liver Transplantation ProgramProfessor of Medicine and SurgeryNorthwestern University Feinberg School of MedicineChicago, Illinois.

Authors: 
Journal:  Gastroenterol Hepatol (N Y)       Date:  2014-06

10.  Practical management of boceprevir and immunosuppressive therapy in liver transplant recipients with hepatitis C virus recurrence.

Authors:  Audrey Coilly; Valérie Furlan; Bruno Roche; Caroline Barau; Coralie Noël; Laurence Bonhomme-Faivre; Teresa Maria Antonini; Anne-Marie Roque-Afonso; Didier Samuel; Anne-Marie Taburet; Jean-Charles Duclos-Vallée
Journal:  Antimicrob Agents Chemother       Date:  2012-08-20       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.